3 Key Takeaways
Plain English Summary- 01Core Finding
Delivered via fingerprinting the polycystic kidney: radiomics of the noncystic parenchyma for, this Phase I/II approach targets Glomerular filtration & renal tubular preservation.
- 02Study Evidence
Tested in a early human trial at the Phase I/II stage.
- 03Practical Meaning
Early-stage human studies — dosing, durability, and rare side effects still require Phase III confirmation.
What This Means for You
Small, cross-sectional, unmatched data require longitudinal validation of reproducibility, prognostic value, and clinical utility.
The Discovery
Autosomal dominant polycystic kidney disease risk stratification relies on total kidney volume, a validated marker of cyst burden and progression. Kremer et al.'s pilot study used rapid breath-hold magnetic resonance fingerprinting with radiomics to evaluate noncystic renal parenchyma in children and young adults. Quantitative T1/T2 texture features distinguished autosomal dominant polycystic kidney disease from controls independently of total kidney volume, cyst fraction, age, or body size, suggesting early tissue changes.
How It Works, Simply
This nephrology research focuses on glomerular filtration & renal tubular preservation. Researchers evaluated it using an early human trial at the Phase I/II stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Delivered via fingerprinting the polycystic kidney: radiomics of the noncystic parenchyma for, this Phase I/II approach targets Glomerular filtration & renal tubular preservation.
- 02Study Evidence
Tested in a early human trial at the Phase I/II stage.
- 03Practical Meaning
Early-stage human studies — dosing, durability, and rare side effects still require Phase III confirmation.
Biological Mechanism & Study Design
Study Design & Cohort
Early human trial
Early human trial · Phase I/II
Biological Pathway & Modality
Glomerular filtration & renal tubular preservation
Intervention: Fingerprinting the polycystic kidney: radiomics of the noncystic parenchyma for
Experimental Findings & Endpoints
Autosomal dominant polycystic kidney disease risk stratification relies on total kidney volume, a validated marker of cyst burden and progression.
Kremer et al.'s pilot study used rapid breath-hold magnetic resonance fingerprinting with radiomics to evaluate noncystic renal parenchyma in children and young adults. Quantitative T1/T2 texture features distinguished autosomal dominant polycystic kidney disease from controls independently of total kidney volume, cyst fraction, age, or body size, suggesting early tissue changes.
Clinical Translation & Practice Context
Small, cross-sectional, unmatched data require longitudinal validation of reproducibility, prognostic value, and clinical utility.
The Bottom Line · Clinical Pearl
“Small, cross-sectional, unmatched data require longitudinal validation of reproducibility, prognostic value, and clinical utility.”
Published in Kidney International · Current Stage: Phase I/II